GlassScriptPhysician profile
Elie Helou
NPI 1912252115
$80,401.47
in general payments reported to CMS, 2019-2025
49 companies · $32K in 2025
The $32K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,495 · 2020: $1,823 · 2021: $4,368 · 2022: $4,419 · 2023: $5,716 · 2024: $28K · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45K · Food and Beverage: $17K · Travel and Lodging: $1,522 · Consulting Fee: $1,300 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,265.00 |
| Food and Beverage | $17,039.45 |
| Travel and Lodging | $1,522.44 |
| Consulting Fee | $1,300.00 |
| Education | $169.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $41,984.98 | 2019-2025 | Biktarvy, Epclusa, Descovy |
| Merck Sharp & Dohme LLC | $13,249.70 | 2019-2025 | Pifeltro, Delstrigo, Capvaxive |
| Viiv Healthcare Company | $6,025.86 | 2019-2025 | Apretude, Dovato, Cabenuva |
| Theratechnologies INC. | $2,838.93 | 2019-2025 | Trogarzo, Egrifta, Egrifta Sv |
| Abbvie INC. | $2,515.38 | 2019-2025 | |
| Amgen INC. | $2,335.20 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,898.95 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Janssen Biotech, INC. | $1,496.33 | 2019-2025 | Symtuza, Prezcobix, Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,442.47 | 2019-2024 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Pfizer INC. | $1,302.50 | 2019-2025 | |
| Janssen Products, LP | $887.83 | 2019-2022 | |
| Lilly USA, LLC | $553.55 | 2019-2024 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $427.27 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $397.07 | 2019-2025 | Xifaxan, Relistor |
| Ardelyx, INC. | $395.62 | 2023-2025 | Ibsrela |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elie Helou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.